Vyne Therapeutics Net Income vs. EBITDA
| VYNE Stock | USD 2.89 0.06 2.03% |
Net Loss | First Reported 2016-12-31 | Previous Quarter -9.4 M | Current Value -12.2 M | Quarterly Volatility 28.6 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.51 | 0.7 |
|
|
For Vyne Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Vyne Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Vyne Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Vyne Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Vyne Therapeutics over time as well as its relative position and ranking within its peers.
Vyne |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.72 | Revenue Per Share 0.016 | Quarterly Revenue Growth 0.467 | Return On Assets (0.35) | Return On Equity (0.60) |
The market value of Vyne Therapeutics is measured differently than its book value, which is the value of Vyne that is recorded on the company's balance sheet. Investors also form their own opinion of Vyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vyne Therapeutics' market value can be influenced by many factors that don't directly affect Vyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Vyne Therapeutics EBITDA vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Vyne Therapeutics's current stock value. Our valuation model uses many indicators to compare Vyne Therapeutics value to that of its competitors to determine the firm's financial worth. Vyne Therapeutics is rated first in net income category among its peers. It is rated first in ebitda category among its peers . At present, Vyne Therapeutics' Net Loss is projected to decrease significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Vyne Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Vyne EBITDA vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Vyne Therapeutics |
| = | (28.45 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Vyne Therapeutics |
| = | (29.26 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Vyne EBITDA Comparison
Vyne Therapeutics is currently under evaluation in ebitda category among its peers.
Vyne Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Vyne Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Vyne Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Vyne Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Vyne Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 29.9 K | 31.4 K | |
| Operating Income | -29.3 M | -30.7 M | |
| Income Before Tax | -27.9 M | -29.3 M | |
| Net Loss | -28.5 M | -29.9 M | |
| Interest Income | 3.6 M | 3.7 M | |
| Net Loss | -29.5 M | -31 M | |
| Total Other Income Expense Net | 1.4 M | 1.5 M | |
| Net Loss | -20.9 M | -21.9 M | |
| Income Tax Expense | 580 K | 609 K | |
| Change To Netincome | -9.6 M | -9.1 M | |
| Net Loss | (2.77) | (2.91) | |
| Income Quality | 0.89 | 0.66 | |
| Net Income Per E B T | 1.02 | 0.79 |
Vyne Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Vyne Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Vyne Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Vyne Therapeutics' important profitability drivers and their relationship over time.
Use Vyne Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vyne Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vyne Therapeutics will appreciate offsetting losses from the drop in the long position's value.Vyne Therapeutics Pair Trading
Vyne Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Vyne Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vyne Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vyne Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vyne Therapeutics to buy it.
The correlation of Vyne Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vyne Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vyne Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vyne Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Vyne Therapeutics position
In addition to having Vyne Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Moderate Funds Thematic Idea Now
Moderate Funds
Funds or Etfs that combine stocks, bonds and money market instruments to get modest capital appreciation over time. The Moderate Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Moderate Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
To fully project Vyne Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Vyne Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Vyne Therapeutics' income statement, its balance sheet, and the statement of cash flows.